MedPath

Thioridazine

Generic Name
Thioridazine
Drug Type
Small Molecule
Chemical Formula
C21H26N2S2
CAS Number
50-52-2
Unique Ingredient Identifier
N3D6TG58NI
Background

A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).

Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.

Indication

For the treatment of schizophrenia and generalized anxiety disorder.

Associated Conditions
Psychosis, Schizophrenia

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

First Posted Date
2014-12-04
Last Posted Date
2018-10-11
Lead Sponsor
Technical University of Munich
Target Recruit Count
21
Registration Number
NCT02307396
Locations
🇩🇪

Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2014-03-26
Last Posted Date
2016-12-07
Lead Sponsor
Ontario Clinical Oncology Group (OCOG)
Target Recruit Count
13
Registration Number
NCT02096289
Locations
🇨🇦

Juravinski Hospital & Cancer Centre, Hamilton, Ontario, Canada

Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

Early Phase 1
Terminated
Conditions
Healthy Subjects
Interventions
First Posted Date
2013-01-10
Last Posted Date
2016-04-14
Lead Sponsor
New Mexico Cancer Care Alliance
Target Recruit Count
6
Registration Number
NCT01765803
Locations
🇺🇸

University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath